Ryan Cunningham

Author Archives

Sera Prognostics Announces Early Limited Commercial Access of Its PreTRM™ Test

SALT LAKE CITY, (GLOBE NEWSWIRE) -- Sera Prognostics, Inc., a women’s healthcare company, today announced a program for early limited commercial access Read more...

Augmenix’ SpaceOAR® System Experiences Rapid U.S. Adoption

WALTHAM, Mass.--(Business Wire)--Augmenix, Inc., a privately held company developing minimally invasive hydrogel products to improve outcomes following Read more...

Announcing BeneClick!, an Employee Benefits Exchange from MassMutual and Maxwell Health uniting Retirement Savings and Health Care Decisions for Consumers

  Why This Matters Americans have a looming retirement savings problem: most of us aren’t saving enough to maintain our standard Read more...

Aria CV, Inc. Closes on $7.8 million Series A Financing

SAINT PAUL, MN — July 24, 2015 — Aria CV, Inc., a developer of medical devices treating pulmonary hypertension, a serious condition that may lead to Read more...

Augmenix Announces Publication of SpaceOAR® System Clinical Trial Results in Leading Radiation Oncology Journal

Pivotal Study Demonstrates Product Safety and Patient Benefits in Men Undergoing Prostate Radiotherapy WALTHAM, Mass.—Augmenix, Inc., a medical Read more...

New England Journal of Medicine Publishes Study Results Suggesting Veracyte’s Percepta™ Bronchial Genomic Classifier Can Reduce Unnecessary Invasive Procedures in Lung Cancer Diagnosis

South San Francisco, Calif., Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced Read more...

100 Women in Hedge Funds: Investing in Healthcare

DATE: Wednesday, April 1st, 2015 at 5:30 PM Boston, MA Healthcare has been on fire! We continue to see significant IPO activity, soaring deal values Read more...

Veracyte Initiates Launch of Percepta™ Bronchial Genomic Classifier

South San Francisco, Calif. - Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostic company pioneering the field of molecular cytology, today announced Read more...

Provision first proton therapy center using new product to benefit prostate cancer patients

KNOXVILLE, Tenn. (WVLT)-- Provision Center for Proton Therapy is helping pioneer a new product that will help further protect prostate cancer patients Read more...

New prostate treatment protects from radiation effects

CHARDON, Ohio -- Two days ago, the FDA approved a new product that protects prostate cancer patients from the side effects of radiation. It's called Read more...

Page 3 of 4« First...234

Contact Info

info@catalysthealthventures.com

(781) 228-5228

50 Braintree Hill Office Park
Suite 301
Braintree, MA 02184